A new treatment of metastatic melanoma: combined therapy with cobimetinib and vemurafenib
This phase 3 study showed an improvement in the response rate and in progression-free survival when cobimetinib was added to vemurafenib. Together with the results of a phase 3 trial comparing dabrafenib plus trametinib with dabrafenib alone,19 these findings provide clear evidence of the benefit of combined MEK and BRAF inhibition. The data combining BRAF